Hubei S&H Law Firm 湖北山河律师事务所 人福医药集团股份公司 2025 年第二次临时股东会 法律意见书 （2025）山河非章第 2539 号 时间（Date）：2025 年 7 月 2 日 致：人福医药集团股份公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会 规则》（以下简称"《股东会规则》"）以及《人福医药集团股份公司章 程》（以下简称"《公司章程》"）《人福医药集团股份公司股东大会议 事规则》（以下简称"《股东大会议事规则》"）等内部规章制度的有关 规定，湖北山河律师事务所（以下简称"本所"）接受人福医药集团股份 公司（以下简称"人福医药"或"公司"）的委托，指派本所执业律师（以 下简称"本所律师"）出席人福医药 2025 年第二次临时股东会（以下简称 "本次股东会"）并出具法律意见。 为出具本法律意见书，本所律师出席了本次股东会，审查了公司提供 的有关本次股东会的相关文件，听取了公司董事会就有关事项所作的说明。 本所已得到人福医药的如下保证：人福医药已向本所提供了出具法律意见 书所必需的、真实的原始书面 ...

人福医药（600079）公告，公司股东招商生命科技(武汉)有限公司及其一致行动人计划在6个月内通过 证券交易所集中竞价交易、大宗交易等合法合规方式增持公司股份，累计增持比例不低于1%，不高于 2%。本次增持价格上限为25.53元/股，资金来源为自有资金及股份增持专项贷款等。增持主体目前合计 持有公司股份4.03亿股，占公司总股本的24.70%。 ...

Group 1 - Hubei Province's direct financing has maintained a high level of around 800 billion yuan for three consecutive years, with nearly 80% of listed companies achieving profitability [1][2] - As of June 30, 2025, Hubei has 191 listed companies, ranking 10th nationally, with 153 domestic and 38 overseas listings [2][3] - The province has a reserve of 1,355 "gold and silver seed" enterprises to support more quality companies to go public [1][4] Group 2 - In Q1 2025, over 70% of Hubei's listed companies were profitable, with notable companies like Jiuzhoutong, CITIC Special Steel, and Wentai Technology reporting revenues exceeding 10 billion yuan [3] - The top ten companies by revenue in Hubei all exceeded 4 billion yuan, indicating strong performance in the region [3] - Hubei has implemented a comprehensive service system for companies to enter the multi-level capital market, aiming to enhance the quality of enterprises [4] Group 3 - Hubei's capital market reforms have led to 20 new listings and approvals annually from 2021 to 2023, with the province ranking 6th nationally for new listings in 2024 [2] - The province aims to achieve five major goals by 2030, including increasing the total number of listed companies and ensuring coverage across all regions [4]

Group 1: Company Announcements - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and international brand image [1] - Saisir reported June sales of 46,086 new energy vehicles, a year-on-year increase of 4.44%, with a total of 172,100 units sold in the first half of the year, down 14.35% year-on-year [1] - Hangzhou High-tech announced a change in controlling shareholder to Jirong Weiye, with stock resuming trading on July 2, 2025 [1] Group 2: Financial Performance - Guomai Technology expects a net profit of 125 million to 156 million yuan for the first half of 2025, a year-on-year increase of 60.52% to 100.33% [2] - Kid King anticipates a net profit of 120 million to 160 million yuan for the first half of 2025, representing a year-on-year growth of 50% to 100% [2] - Mould Technology received a project from a well-known North American electric vehicle company, with expected total sales of 1.236 billion yuan over five years [3] Group 3: Regulatory and Compliance - *ST Yuancheng is under investigation by the China Securities Regulatory Commission for suspected false disclosures in financial reports [4] - The company received a notice of investigation on July 1, 2025, which may lead to significant penalties and potential delisting [4] Group 4: Market Activity - Changcheng Military Industry's stock has experienced significant volatility, with a cumulative price deviation exceeding 20% over three trading days, indicating potential irrational speculation [5] - Anglikang has only one innovative drug project, ALK-N001, currently in Phase I clinical trials, highlighting the long and uncertain nature of drug development [6] Group 5: Sales and Contracts - Beiqi Blue Valley's subsidiary reported a 139.73% year-on-year increase in sales for the first half of the year [7] - Dong'an Power's engine sales in June increased by 82.79% year-on-year [7] - Pudong Construction's subsidiary won multiple major projects with a total bid amount of 1.964 billion yuan [7]

证券代码：600079 证券简称：人福医药 编号：临 2025-084 人福医药集团股份公司 关于盐酸羟考酮片获得药品注册证书的公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 人福医药集团股份公司（以下简称"公司"或"人福医药"）控股子公司宜昌人 福药业有限责任公司（以下简称"宜昌人福"，公司持有其80%的股权）近日收到国 家药品监督管理局核准签发的盐酸羟考酮片的《药品注册证书》。现将批件主要内容 公告如下： 十一、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标 签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可生 产销售。 特此公告。 人福医药集团股份公司董事会 一、药品名称：盐酸羟考酮片 二、批件号：2025S01859、2025S01860 三、剂型：片剂 四、规格：15mg、30mg 五、注册分类：化学药品3类 六、申请事项：药品注册（境内生产） 七、药品批准文号：国药准字H202 ...

Core Viewpoint - The approval of the drug registration certificate for Oxycodone Hydrochloride Tablets by the National Medical Products Administration marks a significant milestone for the company, enabling it to sell the product in the Chinese market [1] Group 1: Company Developments - The company's subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received the drug registration certificate for Oxycodone Hydrochloride Tablets, which are indicated for the relief of moderate to severe cancer pain [1] - The approved specifications for the Oxycodone Hydrochloride Tablets are 15mg and 30mg [1] - The company submitted the marketing authorization application in January 2024, which has been accepted, and the total R&D investment for this project has reached approximately 11 million RMB [1] Group 2: Industry Context - The approval of Oxycodone Hydrochloride Tablets positions the company to compete in the pain management market, particularly for cancer patients [1] - Beijing Huasu Pharmaceutical Co., Ltd. received a drug registration certificate for its 5mg Oxycodone Hydrochloride Tablets in May 2024, indicating a competitive landscape in the market [1]

Group 1 - Multiple companies are involved in various acquisition and joint venture cases, with completion dates primarily set for June 2025 [1][2][3] - Notable transactions include the acquisition of shares by China Logistics Co., Ltd. from Xuzhou Xugong Intelligent Cloud Warehouse Co., Ltd. and the establishment of a joint venture between Warner Bros. Discovery and Jinjiang International Group [1][2] - The transactions span various industries, including pharmaceuticals, renewable energy, and automotive sales, indicating a diverse investment landscape [1][2][3] Group 2 - The acquisition cases involve significant players such as Amperex Technology Limited and Stonepeak Partners LP, highlighting the interest in renewable energy and technology sectors [1][2] - The establishment of joint ventures, such as that between Japan Paper Corporation and Sumitomo Corporation, reflects ongoing collaboration trends in the materials and manufacturing industries [1][2][3] - The involvement of investment management firms like British Columbia Investment Management Corporation and Ethos Capital demonstrates the role of institutional investors in these transactions [1][2]

特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 人福医药集团股份公司（以下简称"人福医药"或"公司"）于2025年1月15日 披露《人福医药集团股份公司关于回复上海证券交易所的关于公司持股5%以上股东权 益变动有关事项监管工作函的公告》，公司5%以上股东宜昌产投控股集团有限公司（以 下简称"宜昌产投"）就收购芜湖信福股权投资合伙企业（有限合伙）（以下简称"芜 湖信福"）份额事宜作出承诺。近日，公司收到《宜昌产投控股集团有限公司关于收 购信达所持芜湖信福份额的情况说明》（以下简称"《情况说明》"），主要内容如 下： 一、原工作计划 证券代码：600079 证券简称：人福医药 编号：临 2025-083 人福医药集团股份公司 关于公司持股 5%以上股东收购芜湖信福股权投资合伙企 业（有限合伙）份额的进展公告 根据《上市公司监管指引第4号——上市公司及其相关方承诺》等相关规定，宜 昌产投本次涉及变更承诺。宜昌产投在《情况说明》中承诺将按照相关规定尽快履行 变更承诺的工作程序。 特此公告。 人福医药集团股份公司董事会 ...

Company Highlights - Hanyu Pharmaceutical expects a net profit of 142 million to 162 million yuan for the first half of 2025, benefiting from increased global market demand and successful product approvals [1] - Taotao Automotive anticipates a net profit growth of 70% to 98% year-on-year for the first half of 2025, driven by enhanced brand influence and improved operational efficiency [2] - Xiaogoods City projects a net profit increase of 13% to 17% for the first half of 2025, attributed to growth in main business revenue and trade fulfillment services [2] - Hongxin Electronics signed contracts totaling 373 million yuan for computing power services through its subsidiaries [3] - Alloy Investment's controlling shareholder will change to Jiuzhou Hengchang, leading to the resumption of trading [3] - Hangzhou High-tech is planning a change in control, with a suspension of trading expected for no more than two trading days [4] - Junpu Intelligent signed a sales framework contract for humanoid robots worth 28.25 million yuan [7] - Lens Technology plans to issue 262 million H-shares globally, with an initial price range set between 17.38 and 18.18 HKD [8] - Saintno Biopharmaceuticals received a drug registration certificate for its product, further enhancing its market competitiveness [12] Investment & Contracts - Shenzhen Energy plans to invest 6.332 billion yuan in upgrading the Mawan Power Plant, aligning with national energy policies [17] - China Railway Construction won a contract worth 3.781 billion yuan for the China-Kyrgyzstan-Uzbekistan railway project [27] - China Railway secured contracts totaling approximately 5.343 billion yuan for the same railway project [28] - Zhongtian Technology's subsidiary won multiple marine energy project contracts totaling about 1.722 billion yuan [29] - Lande Group intends to acquire a 20.1667% stake in Jujia Technology for up to 121 million yuan, enhancing its capabilities in high-performance materials [21][22] Financing & Capital Increase - Yiwei Lithium Energy submitted an application for H-share issuance and listing in Hong Kong [30] - Jiadou Technology plans to issue H-shares and list on the Hong Kong Stock Exchange [30] - Helin Micro-Nano is preparing to issue H-shares for listing in Hong Kong [30] Other Developments - Renfu Pharmaceutical received approval for its midazolam injection in France, with expected annual sales of approximately 33 million USD [31] - Kanghong Pharmaceutical obtained a drug registration certificate for its eye drop product, enhancing its product pipeline in the ophthalmology sector [32]

MIDAZOLAM QBD GROUP AUSTRIA 1 mg/mL, solution injectable/pour perfusion MIDAZOLAM QBD GROUP AUSTRIA 5 mg/mL, solution injectable/pour perfusion 规格：1mg/ml（装量：5mL）和5mg/ml（装量：1mL、3mL和10mL） 生产企业：宜昌人福药业有限责任公司 区域：法国 咪达唑仑注射液获得法国国家药品和健康产品安全局（ANSM）的上市许可，被 批准的适应症包括：1）在诊断或治疗性操作前后及过程中进行清醒镇静（无论是否 联合局部麻醉）；2）成人麻醉诱导前的术前用药、麻醉诱导、以及与其他麻醉剂作 为镇静药物联合使用；儿童麻醉诱导前的术前用药；3）重症监护病房（ICU）中的 镇静。宜昌人福于2023年12月以DCP（Decentralized Procedure）程序提交咪达唑仑注 射液上市许可申请并获得受理，现获得法国国家药品和健康产品安全局（ANSM）上 市批准，有效期五年，本项目累计研发投入约为800万元人民币。根据IQVIA数据统 计，2024年咪达唑仑注射液在 ...